Cargando…
Improving predictability of IgE-high type 2 chronic sinusitis with nasal polyps in the biologic era
BACKGROUND: Chronic rhinosinusitis (CRS) is an inflammatory disease that may require biological therapy. Omalizumab is an anti-IgE biologic that was recently approved by the FDA and Health Canada for use in severe CRS with nasal polyps (CRSwNP) recalcitrant to intranasal corticosteroids. Dosing is b...
Autores principales: | Heffernan, Austin, Phulka, Jobanjit, Thamboo, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128111/ https://www.ncbi.nlm.nih.gov/pubmed/35606866 http://dx.doi.org/10.1186/s40463-022-00580-y |
Ejemplares similares
-
Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
por: Kariyawasam, Harsha H, et al.
Publicado: (2020) -
Comparison of Blood and Tissue Eosinophil Count and Blood IgE in Patients with Chronic Sinusitis and Nasal Polyps
por: Asghari, Masoud, et al.
Publicado: (2021) -
Role of IgG, IgA, and IgE antibodies in nasal polyp tissue: their relationships with eosinophilic infiltration and degranulation.
por: Suh, Kyung-Sik, et al.
Publicado: (2002) -
Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue
por: Patou, Joke, et al.
Publicado: (2009) -
Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada
por: Yong, Michael, et al.
Publicado: (2023)